Meeting
2020 ASCO Virtual Scientific Program
Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).
Authors
Milind M. Javle
The University of Texas MD Anderson Cancer Center, Houston, TX
Milind M. Javle , Do-Youn Oh , Masafumi Ikeda , Wei-Peng Yong , Nicola McIntyre , Bertil Lindmark , Mark McHale
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03093870
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4597)
DOI
10.1200/JCO.2020.38.15_suppl.4597
Abstract #
4597
Poster Bd #
205
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).
First Author: Milind M. Javle
Poster
2019 Gastrointestinal Cancers Symposium
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).
First Author: Do-Youn Oh
Poster
2019 Gastrointestinal Cancers Symposium
Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
First Author: Aaron C. Tan
Poster
2021 Gastrointestinal Cancers Symposium
Phase Ib trial of varlitinib plus weekly paclitaxel in EGFR/HER2 co-expressing advanced gastric cancer (AGC).
First Author: Yunbeom Sang